They create a molecule that could be used as a parkinson’s treatment
400
In a research led by the General Council of Scientific Research (CSIC) a molecule (S14) has been created that reduces neuroinflammation and the death of neurons in the cerebral region that affects Parkinson. The results obtained in the mouse models used in Parkinson's research have been satisfactory and foresee that during a couple of years clinical trials could be initiated to study molecular influence in humans. XI in Florence. The results have been presented at the International Congress of Alzheimer and Parkinson.
“The neuronal loss associated with the disease could be slowed down thanks to the mechanism of influence of this molecule,” says Ana Martínez, a researcher at the Institute of Medical Chemistry. In fact, during the study they have found that the compound S14 causes the formation of dopaminergic neurons in mouse models. Dopaminergic neurons are those that are gradually lost by people affected by Parkinson's disease. “We have already started the preclinical research work and so we can start the clinical phase in two years with humans,” added Martínez.
Currently, one in 1,000 people suffer from Parkinson, the second most common neurodegenerative disease in older people after Alzheimer's disease.
Zu idazle
Zientzia aldizkaria
